Edition:
United States

Aratana Therapeutics Inc (PETX.OQ)

PETX.OQ on NASDAQ Stock Exchange Global Market

5.90USD
26 May 2017
Change (% chg)

$-0.02 (-0.34%)
Prev Close
$5.92
Open
$5.90
Day's High
$5.99
Day's Low
$5.78
Volume
70,617
Avg. Vol
133,193
52-wk High
$10.71
52-wk Low
$4.98

Latest Key Developments (Source: Significant Developments)

Aratana Therapeutics Q1 loss per share $0.34
Monday, 8 May 2017 04:30pm EDT 

May 8 (Reuters) - Aratana Therapeutics Inc ::Aratana therapeutics reports first quarter 2017 financial results.Q1 loss per share $0.34.Q1 revenue $3.8 million.Aratana therapeutics inc - for full year 2017, company estimates operating expenses of approximately $45 million.  Full Article

Aratana Therapeutics provides update on Entyce
Tuesday, 25 Apr 2017 04:30pm EDT 

April 25 (Reuters) - Aratana Therapeutics Inc -:Aratana Therapeutics provides update on Entyce®.Aratana-Recently met with U.S. Food and drug administration center for veterinary medicine regarding proposed manufacturing transfer of entyce.Believes that it is in agreement with cvm on how to proceed.Aratana Therapeutics Inc - if submission is approved, aratana believes it would be able to make entyce commercially available by fall of 2017.Aratana therapeutics inc - intends to resubmit required prior approval submission in coming weeks relating to entyce.Says believes it would be able to make entyce commercially available by fall of 2017.  Full Article

Aratana Therapeutics posts Q4 loss per share $0.64
Monday, 13 Mar 2017 04:26pm EDT 

Aratana Therapeutics Inc : Aratana Therapeutics reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.64 . Q4 revenue $292,000 .Aratana Therapeutics Inc - expects cash, cash equivalents and short-term investments will fund operations and debt obligations through March 31, 2018.  Full Article

Aratana therapeutics anticipates that Entyce will be commercially available by late-2017
Monday, 6 Feb 2017 08:09am EST 

Aratana Therapeutics Inc : Anticipates that Entyce will be commercially available by late-2017 . Also conducting additional clinical work in other surgical procedures to potentially expand label for Nocita in dogs . Received response from FDA in connection with post-approval supplement request to transfer manufacturing of Entyce to new vendor .FDA has requested additional information regarding proposed transfer.  Full Article

Aratana Therapeutics reports Q3 financial results
Thursday, 3 Nov 2016 05:00pm EDT 

Aratana Therapeutics Inc : Continues to anticipate commercial launch of ENTYCE in Q1 of 2017 . Aratana Therapeutics reports third quarter 2016 financial results .Q3 loss per share $0.38.  Full Article

Aratana Therapeutics granted FDA approval of Nocita
Monday, 15 Aug 2016 04:30pm EDT 

Aratana Therapeutics Inc : Aratana Therapeutics granted FDA approval of Nocita® (bupivacaine liposome injectable suspension) .Anticipates Nocita will be commercially available to veterinarians in fall of 2016.  Full Article

Aratana posts Q2 EPS $0.61
Thursday, 4 Aug 2016 04:20pm EDT 

Aratana Therapeutics Inc : Q2 earnings per share $0.61 . Aratana therapeutics reports second quarter 2016 financial results .Q2 revenue $38 million versus $45 million.  Full Article

Aratana Therapeutics posts Q2 earnings per share $0.61
Thursday, 4 Aug 2016 04:20pm EDT 

Aratana Therapeutics Inc : Q2 revenue $38 million versus $230,000 . Aratana Therapeutics reports second quarter 2016 financial results .Q2 earnings per share $0.61.  Full Article

Aratana Therapeutics files for FDA approval of Nocita
Thursday, 30 Jun 2016 09:00am EDT 

Aratana Therapeutics Inc : Aratana Therapeutics files for FDA approval of Nocita(bupivacaine liposome injectable suspension) . Says animal drug user fee act (ADUFA) date for approval is August 28, 2016 . Aratana anticipates Nocita will be commercially available to veterinarians in fall of 2016 .Says anticipates Nocita will be commercially available to veterinarians in fall of 2016.  Full Article

Aratana Therapeutics receives CMC technical section complete letter
Thursday, 2 Jun 2016 09:23am EDT 

Aratana Therapeutics Inc : Received a technical section complete letter for chemistry, manufacturing and controls for nocita . Aratana Therapeutics receives CMC technical section complete letter for post-operative pain therapeutic .If nocita receives FDA approval, aratana expects to commence commercialization in late-2016.  Full Article

More From Around the Web

BRIEF-Aratana Therapeutics Q1 loss per share $0.34

* Aratana therapeutics reports first quarter 2017 financial results